Imagen de Portada

Letter: Pharmacotherapy for Alcohol Dependence in Cirrhosis—By Addressing One Issue Do We Create Another?

Fuente: Wiley Open Access

Guardado en:

Detalles Bibliográficos
Autores principales:	Andrew W. Nguyen, Dorothy Liu, Sarah Lucas, Karl Vaz
Formato:	Artículo Open Access
Publicado:	Wiley 2026
Materias:	Alimentary Pharmacology & Therapeutics
Acceso en línea:	Acceder al recurso
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Letter: The Unresolved Issue of NSBB Confounding in Statin Research for Cirrhosis
por: Deliang Huang, et al.
Publicado: (2026)

Letter: Statins for Cirrhosis: Are We Ready to Move From Cardiovascular Prophylaxis to Portal Pressure Management?
por: Abdulrahman Ismaiel
Publicado: (2026)

Letter: Refining Mortality Estimates in Severe Alcohol‐Associated Hepatitis—Addressing Heterogeneity and Prognostic Assessment
por: Shupeng Zhao, et al.
Publicado: (2025)

Letter: Refining Mortality Estimates in Severe Alcohol–Associated Hepatitis—Addressing Heterogeneity and Prognostic Assessment. Authors' Reply
por: Francisco Idalsoaga, et al.
Publicado: (2025)

Letter: Amino Acid Imbalance Is an Independent Factor for Mortality in Patients With Liver Cirrhosis
por: Zhanbo Qu
Publicado: (2026)

Letter: Timely Follow‐Up in Cirrhosis—A Key Public Health Intervention
por: Mo‐Yao Tan, et al.
Publicado: (2024)

Letter on: ‘Impact of Frailty on the Prognosis of Patients With Liver Cirrhosis Undergoing Insertion of a TIPS ’
por: Sai Kiran Kuchana, et al.
Publicado: (2026)

Letter: Amino Acid Imbalance and Mortality in Cirrhosis—Interpretation and Methodological Considerations. Authors' Reply
por: Yuki Utakata, et al.
Publicado: (2026)

Assessing Major Adverse Liver Outcomes With Baclofen Compared to Acamprosate in Compensated Alcohol‐Associated Cirrhosis
por: Yee Hui Yeo, et al.
Publicado: (2026)

Letter on: ‘Impact of Frailty on the Prognosis of Patients With Liver Cirrhosis Undergoing Insertion of a TIPS ’. Authors' Reply
por: Christian Labenz, et al.
Publicado: (2026)

Letter: Predictors of Corticosteroid Response in Alcohol‐Related Hepatitis
por: Ewan Forrest, et al.
Publicado: (2025)

Letter: Statins for Cirrhosis: Are we Ready to Move From Cardiovascular Prophylaxis to Portal Pressure Management? Authors' Reply
por: Bernardo de Faria Moraes, et al.
Publicado: (2026)

Letter: Addressing opioid exposure and associated harms in patients with IBD
por: Christian P. Selinger, et al.
Publicado: (2024)

Letter: Disease Stage and Absolute Risk in Evaluating the Branched‐Chain Amino Acid to Tyrosine Ratio in Cirrhosis. Authors' Reply
por: Takao Miwa, et al.
Publicado: (2026)

Letter: Predictors of Corticosteroid Response in Alcohol‐Related Hepatitis—Authors' Reply
por: Francisco Idalsoaga, et al.
Publicado: (2025)

Letter: Addressing Gaps in Hospital‐Based Hepatitis C Screening—Insights and Recommendations
por: Zhen Deng, et al.
Publicado: (2025)

Letter: Safety and Tolerability of Injectable Extended Release Naltrexone for the Management of Alcohol Use Disorder in Advanced Alcohol‐Associated Liver Disease
por: Xing Bai, et al.
Publicado: (2025)

Differential Characteristics and Survival Outcomes of Patients With Cirrhosis According to Underlying Liver Aetiology
por: Yu Shi, et al.
Publicado: (2025)

Letter: Attempted Validation of Villin‐1 as a Gut Barrier Marker in Decompensated Cirrhosis—Potential Confounding by Tubular Injury and Aetiology. Authors' Reply
por: David Tornai, et al.
Publicado: (2026)

Letter: Enhancing patient support through social work—Addressing economic challenges and medication non‐adherence in liver disease management
por: Min Wu, et al.
Publicado: (2024)

Letter: Safety and Tolerability of Injectable Extended‐Release Naltrexone for the Management of Alcohol Use Disorder in Advanced Alcohol‐Associated Liver Disease—Authors' Reply
por: Luis Antonio Díaz, et al.
Publicado: (2025)

Letter: Optimising public health policies to combat alcohol‐associated liver disease in youth—Addressing key methodological and regional challenges
por: Rui Zhang, et al.
Publicado: (2024)

Letter: Towards Better Intervention Strategies for MASLD and MetALD—What Are We Missing?
por: Qiang Hu, et al.
Publicado: (2024)

Letter: Addressing Gaps in Hospital‐Based Hepatitis C Screening—Insights and Recommendations. Authors' Reply'
por: Alberto Ferrarese, et al.
Publicado: (2025)

Letter: Refining the Understanding of Hepatic Steatosis and Cardiovascular Risk—Addressing Key Variables and Subgroup Analyses
por: Changhu Sun, et al.
Publicado: (2025)

Letter: Liver Transplantation Outcomes for Alcohol‐Associated Liver Disease—Commentary on an Individual Patient Data Meta‐Analysis and Future Research Directions
por: Xinglin Li, et al.
Publicado: (2026)

Barriers to Medical Care Are Frequently Reported by Patients With Cirrhosis
por: William Chai, et al.
Publicado: (2025)

Letter on ‘Meta‐Analysis: Mortality Trends and Risk Factors in Severe Alcohol‐Associated Hepatitis’—Authors' Reply
por: Francisco Idalsoaga, et al.
Publicado: (2025)

Letter: Towards Better Intervention Strategies for MASLD and MetALD—What Are We Missing? Authors' Reply
por: Yewan Park, et al.
Publicado: (2024)

Letter: Enhancing Predictive Models for Paediatric Ulcerative Colitis—Addressing Socioeconomic, Environmental and Clinical Factors. Authors' Reply
por: Merle Claßen, et al.
Publicado: (2024)

Editorial: Another brick in the CDST wall
por: Aurelien Amiot, et al.
Publicado: (2024)

Letter: Antiviral Prophylaxis Mitigates HBV Reactivation Risk During Cancer Immunotherapy: Unresolved Challenges and Future Directions—Authors' Reply
por: Landon Long Chan, et al.
Publicado: (2025)

Editorial: Diabetes Management in Cirrhosis—The Window of Opportunity Before Decompensation
por: Thanawin Pramotedham, et al.
Publicado: (2026)

Editorial: Timely Follow‐Up in Cirrhosis: How Does It Work?
por: Nina Kimer, et al.
Publicado: (2024)

Editorial: Statin Therapy in Cirrhosis: More Than Just Lipid‐Lowering
por: Emily Stephenson, et al.
Publicado: (2026)

Amino Acid Imbalance Is an Independent Factor for Mortality in Patients With Liver Cirrhosis
por: Yuki Utakata, et al.
Publicado: (2026)

Editorial: Linking Patients With Cirrhosis to Clinical Care—The Hurdles and Way Forward
por: Jimmy Che‐To Lai, et al.
Publicado: (2026)

Unstable Recompensation: An Intermediate Subtype in Patients With HBV ‐Related Decompensated Cirrhosis
por: Shuai Xia, et al.
Publicado: (2025)

Letter: Critical appraisal of biologic therapy in early ulcerative colitis management—Addressing study limitations and the role of psychological resilience—Authors' reply
por: Vibeke Strande, et al.
Publicado: (2024)

Editorial: Another brick in the CDST wall: Authors' reply
por: Kyuwon Kim, et al.
Publicado: (2024)